Alnylam Pharmaceuticals, Inc. (ALNY)
$
434.07
-21.97 (-5.06%)
Key metrics
Financial statements
Free cash flow per share
1.6841
Market cap
57.3 Billion
Price to sales ratio
17.8646
Debt to equity
11.8571
Current ratio
2.5412
Income quality
6.1027
Average inventory
73.5 Million
ROE
0.2613
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics based on ribonucleic acid interference. The company reported selling, general, and administrative expenses of $975,526,000.00 indicating its operational overhead costs. Additionally, the company incurred an interest expense of $141,858,000.00 reflecting its debt servicing obligations. A net loss of -$278,157,000.00 was reported, indicating challenges in its operations. With its stock identified by the symbol 'ALNY' in the market, the weighted average number of diluted shares outstanding is 127,651,000.00 reflecting potential dilution effects. Alnylam's pipeline of investigational RNAi therapeutics addresses a range of conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Marketed products such as ONPATTRO (patisiran), GIVLAARI, and OXLUMO highlight its commitment to addressing unmet medical needs. Furthermore, the company is advancing multiple candidates in its pipeline, including givosiran and cemdisiran, enhancing its portfolio with potential therapies for various diseases. Strategic collaborations with prominent partners like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme bolster its development capabilities. The stock is priced at $453.56 positioning it in the higher-end market. It has an average trading volume of 1,158,259.00 indicating moderate liquidity. With a mid-range market capitalization of $57,346,644,979.00 the company is a steady performer in the competitive landscape. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within the field. Alnylam continues to enhance its position through collaborations and partnerships, unlocking new avenues for discovering and delivering RNAi therapeutics. The company's focus on cutting-edge science and strategic alliances marks it as a noteworthy entity in advancing healthcare solutions and addressing complex diseases. As it navigates its challenges, Alnylam remains committed to its vision of transforming the treatment landscape through pioneering biopharmaceutical innovations.
Is Alnylam Pharmaceuticals, Inc. (ALNY) a good investment?
Investing in Alnylam Pharmaceuticals, Inc. (ALNY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Alnylam Pharmaceuticals, Inc. (ALNY)'s stock forecast?
Analysts predict Alnylam Pharmaceuticals, Inc. stock to fluctuate between $205.87 (low) and $495.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alnylam Pharmaceuticals, Inc.'s market capitalization?
As of 2025-11-03, Alnylam Pharmaceuticals, Inc.'s market cap is $57,346,644,979, based on 132,113,818 outstanding shares.
How does Alnylam Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alnylam Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alnylam Pharmaceuticals, Inc. (ALNY) stock?
To buy Alnylam Pharmaceuticals, Inc. (ALNY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALNY. Place an order (Market, Limit, etc.).
What is the best time to invest in Alnylam Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alnylam Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $2,248,243,000 | EPS: -$2.18 | Growth: -38.07%.
Where can I find Alnylam Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.alnylam.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alnylam Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Alnylam Pharmaceuticals, Inc. stock?
All-time high: $495.55 (2025-10-20) | All-time low: $117.58 (2022-05-12).
What are the key trends affecting Alnylam Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
seekingalpha.com
Alnylam Pharmaceuticals, Inc. ( ALNY ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Pushkal Garg - EVP of Development & Medical Affairs and Chief Research & Dev. Officer Jeffrey Poulton - CFO & Executive VP Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Huidong Wang - Barclays Bank PLC, Research Division Ritu Baral - TD Cowen, Research Division Adithya Jayaraman - Evercore Inc. Presentation Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals 3Q 2025 Earnings Conference Call.
zacks.com
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Here is how Alnylam Pharmaceuticals (ALNY) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
zacks.com
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from a post hoc analysis of the HELIOS-B.
See all news
